340B and Healthcare Investing: How a Drug Pricing Program Can Shape Deal Decisions
Published by RichStorm.co
Key Takeaways
Treat 340B exposure as a quality-of-earnings issue first. Investors should separate durable operating earnings from profits that depend on 340B pricing and assess whether those economics are likely to persist through the investment period.
340B risk is asymmetric and event-driven. Manufacturer restrictions, state laws, court decisions, and changes in federal policy can quickly affect eligible volume and profitability, while favorable developments may simply preserve economics already reflected in current earnings.
Quantify the downside rather than applying a general “policy risk” discount. Diligence should identify how much EBITDA depends on 340B and model the impact of a 25%, 50%, or 100% reduction in the relevant spread.
Exposure varies significantly by business model. Specialty and contract pharmacies, hospital-affiliated infusion businesses, physician groups, and 340B technology vendors can all be affected differently, requiring different diligence and valuation approaches.
340B is no longer a niche drug discount program. In 2025, purchases of discounted drugs under 340B reached approximately $100 billion. For many healthcare assets, 340B has become a material—but not always easy to identify—factor in the income statement, and it can also change how investors assess asset value.
For investors, the key question is: how much of a target company’s EBITDA depends on a drug discount that may be affected by regulation, court decisions, or changes in agency policy?
The answer can vary significantly across specialty pharmacies, infusion businesses, physician groups, and software vendors.
What Is 340B?
Under Section 340B of the Public Health Service Act, manufacturers participating in Medicaid must offer eligible outpatient drugs to qualifying healthcare organizations, known as “covered entities,” at or below a statutory ceiling price. When payer reimbursement exceeds a covered entity’s acquisition cost, the difference can create economic value for the covered entity. This spread is one of the key sources of 340B-related economics relevant to investors.
In 2025, 340B purchases reached $100.0 billion, up 22.8% from $81.4 billion in 2024. Hospitals accounted for the large majority of program purchases. Drug Channels Institute has estimated the value of 340B discounts—the difference between purchases at list prices and at 340B prices—at roughly $79.5 billion in 2025; this estimate should not be interpreted as covered-entity profit, because the economic value ultimately realized depends on reimbursement, fees, operating costs, and other factors.
What this means for investors: The program is now too large to ignore, and because its growth has been driven primarily by hospitals, it is also a major focus for regulators and manufacturers. When evaluating a 340B-related business, the first step is to determine how much of its profit comes from the spread.
How 340B Changes Investment Decisions
The program affects healthcare assets in different ways, and each type of exposure requires a different valuation treatment:
Revenue the asset earns
340B directly becomes revenue for the business. For example, a contract pharmacy dispensing prescriptions for a hospital can earn dispensing fees and, in some cases, a share of the spread. This is the income the business actually “earns.”
Costs the asset avoids
340B lowers costs rather than increasing revenue. For example, a hospital-owned or hospital-affiliated outpatient infusion site that operates under the hospital’s 340B registration may be able to purchase drugs at 340B prices. Most independent home infusion operators are not covered entities and do not access 340B pricing directly, so this effect applies mainly to hospital-linked sites. Margin improves because the business spends less, not because it collects more.
Referral volume that the asset depends on
The business may not earn the 340B spread directly, but its patients or orders may be driven by 340B economics. For example, a hospital system may direct patients to certain infusion providers because of 340B. If the rules change, referrals may decline, and the business may be affected.
A driver of demand for the asset’s product
340B can create customer demand for a product or service. For example, hospitals need 340B management software to handle eligibility and replenishment. As 340B grows, demand grows—but that demand also changes with the rules.
One practical underwriting approach is to value the durable core business separately from 340B-dependent economics and stress-test whether those economics persist through exit. For a specialty pharmacy or hospital-affiliated infusion business, 340B-related economics may represent a meaningful share of EBITDA, so a reduction can materially change value. For physician groups, the effect may be more indirect: research from the USC Schaeffer Center argues that spread pricing can create incentives for hospitals to acquire physician practices or infusion centers. For vendors, 340B can be a demand driver, but eligible transaction volume depends on rules the vendor does not control.
What this means for investors: The first issue is the quality of earnings, and only then policy risk. Quality of earnings asks how much of reported EBITDA is sustainable and repeatable, versus how much depends on special conditions. Because 340B economics depend partly on statutory and regulatory conditions outside the company’s control, their durability may differ from earnings generated primarily through the underlying operations. Regardless of whether policy changes, investors should first quantify the spread and determine how concentrated it is across customers. Only after that can they see how much EBITDA is actually exposed to policy risk.
Three Risks That Could Compress the Spread
Manufacturer restrictions, state laws, and courts: More than 40 manufacturers currently restrict which contract pharmacies can receive drugs at 340B prices, while at least 21 states had enacted laws protecting contract pharmacy access as of October 2025. Court outcomes have been inconsistent, so exposure depends on the state and the applicable federal circuit. In diligence, the practical task is to map the target’s volume by state rather than assume a single nationwide outcome.
HRSA rebate-model pilot: The earlier rebate-model pilot was vacated by a federal district court on February 10, 2026. HRSA subsequently announced a revised pilot in August 2026, with approved manufacturer plans scheduled to take effect January 1, 2027. The revised pilot is limited to selected drugs in the Medicare Drug Price Negotiation Program for the 2026 and 2027 price-applicability years. It does not change the statutory 340B ceiling price; instead, it changes the timing and mechanism through which the discount is effectuated, potentially creating working-capital and administrative burdens for covered entities. Because the pilot is limited in scope, its immediate financial effect may be modest, but it provides a framework investors should monitor if rebate-based models expand.
Medicare price negotiation: The Medicare Drug Price Negotiation Program includes nonduplication rules intended to prevent manufacturers from being required to provide both Maximum Fair Price (MFP) access and a 340B discount on the same unit when the 340B ceiling price is lower. The interaction between MFP access and 340B pricing therefore adds operational complexity and can change the economics of selected high-spend drugs. Investors should model this exposure at the drug level rather than assume a uniform effect across the portfolio.
What this means for investors: These risks are asymmetric and event-driven. “Event-driven” means value may change abruptly when a specific event occurs—for example, a manufacturer restriction, court ruling, or agency announcement—rather than deteriorating gradually. “Asymmetric” means positive and negative events have different effects: for the party earning the spread, a negative event can sharply reduce revenue, while a positive event often only preserves the status quo because the spread is already embedded in current earnings. Investors therefore should not price the asset only around an “average case”; they should separately model what happens if the spread is reduced.
Diligence Framework: Turn Policy Risk into a Sensitivity Table
The goal is to answer one question in dollars: if the spread is reduced by 25%, 50%, or 100%, how much EBITDA remains? Five workstreams can provide the answer.
Break down revenue: Separate gross profit into service and dispensing fees, non-340B drug margin, and 340B spread, calculated by customer and by drug.
Check concentration: Identify the covered-entity customers and manufacturers that account for the largest share of 340B volume.
Map volume by state: State protection laws and court outcomes differ.
Flag drugs subject to Medicare price negotiation: Identify selected drugs affected by MFP rules and, where applicable, the revised 340B rebate-model pilot.
Model working capital: If the rebate model expands, covered entities may have to pay the full amount upfront and receive the rebate later.
The output should be a bridge from reported EBITDA to a 340B-adjusted downside case that can be carried directly into valuation and return analysis.
Illustrative example: Consider a hypothetical specialty pharmacy acquired at 12.0x reported EBITDA of $30 million, of which $10 million comes from 340B spread (net of fees and operating costs). The buyer finances the deal with $150 million of debt, or 5.0x EBITDA.
Three points stand out. First, because value is set as a multiple of EBITDA, every $1 of spread lost removes $12 of enterprise value; eliminating the spread removes one-third of it. Second, leverage amplifies the effect on equity. In the base case, equity is worth $210 million ($360 million less $150 million of debt); if the spread disappears, equity falls to $90 million, a 57% decline, even though EBITDA fell by only one-third. Third, leverage rises from 5.0x to 7.5x, which may breach covenants well before any exit.
This is why the durable core business and the 340B-dependent economics should be valued separately. If a buyer applies 12.0x to the $20 million core and only 6.0x to the $10 million spread to reflect its policy risk, the implied value is $300 million rather than $360 million. The $60 million gap is effectively the price of 340B risk, and it is the number that should be negotiated, rather than debated as a general policy concern.
Figures are hypothetical and for illustration only.
Case Study: Sentry Data Systems
Sentry Data Systems is a pharmacy procurement, compliance, analytics, and 340B technology business that was acquired by private equity firm Abry Partners in 2015 and sold to healthcare technology company Craneware for $400 million in 2021. Its subsequent performance provides a useful illustration of how 340B-related exposure can change over an ownership cycle.
There are two useful observations. First, the risk was visible before the exit, but its size was not. Manufacturer restrictions began about nine months before Abry announced the sale, when only a small number of manufacturers were involved. Over Craneware’s ownership, the number grew to more than 40, and by FY26 the restrictions were cited as a direct drag on revenue. The timing of ownership therefore determined not whether an owner faced the risk, but how much of it showed up in earnings. Second, high customer retention does not necessarily insulate revenue from policy risk: if a business recognizes revenue based on eligible 340B activity, external restrictions can slow that activity even when customers remain in place.
The episode does not establish that Abry timed its exit around regulation. It does show how a risk that is still early at exit can look manageable to one owner and become a material earnings issue for the next. Customer retention and demand may remain strong even as external restrictions change the volume of eligible 340B activity and, in turn, reported revenue.
What this means for investors: This case is a reminder that when acquiring a 340B-related business, it is not enough to ask whether customers will stay. Investors also need to understand what drives billing and whether transaction volume can be changed by external decisions.
Conclusion
For healthcare investors, 340B is ultimately a question of earnings durability. The program can create meaningful value, but that value may depend on rules and external decisions outside a company’s control. Understanding that distinction helps investors assess not only current earnings, but how much of that value is likely to persist through an investment period.
ABOUT THE AUTHOR
Sandy Juan
Sandy Juan is a pharmacist and Master of Biotechnology candidate at the University of Pennsylvania. Her experience spans healthcare consulting, biotechnology research, and healthcare private equity. She is particularly interested in the intersection of science, healthcare, and investing, with a focus on translating scientific and clinical insights into investment perspectives.
References
HRSA. “2025 340B Covered Entity Purchases.” July 2026.
HRSA. “2024 340B Covered Entity Purchases.” December 2025.
Drug Channels Institute (Adam J. Fein). “The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?” July 15, 2026.
HRSA. “Notice Regarding 340B Rebate Model Pilot Program.” Federal Register, August 2026.
CMS. “Manufacturer Effectuation of the Maximum Fair Price in 2028: Draft Guidance Fact Sheet.” July 16, 2026.
CMS. “Selected Drugs and Negotiated Prices.”
USC Schaeffer Center. “Reform of Federal Drug Discount Program Should Target Misaligned Incentives.” September 29, 2025.
340B Report. “Contract Pharmacy Restrictions Tracker.” Accessed September 2026.
NACHC. “A Year in Review: State Legislative Trends in 340B in 2025.” October 17, 2025.
Quarles & Brady. “Drug Manufacturers Cut Off 340B Pricing for Contract Pharmacies.” September 30, 2020.
Abry Partners. “Abry Partners Announces Sale of Sentry Data Systems for $400 Million.” June 8, 2021.
Craneware plc. “FY26 Trading Update.” July 3, 2026.
Investing.com. “Why Is Craneware Stock Plunging Today?” July 3, 2026.
